Valuation: Lineage Cell Therapeutics, Inc.

Market Cap 252M 226M 209M 189M 354M 23.95B 358M 2.51B 995M 12.55B 946M 926M 39.81B P/E 2026 *
-16.6x
P/E 2027 * -7.77x
Enterprise Value 252M 226M 209M 189M 354M 23.95B 358M 2.51B 995M 12.55B 946M 926M 39.81B EV / Sales 2026 *
16.6x
EV / Sales 2027 * 15x
Free-Float
95.14%
Yield 2026 *
-
Yield 2027 * -
1 day+1.82%
1 week+4.36%
Current month+6.20%
1 month+4.53%
3 months-1.46%
6 months-34.52%
Current year-39.22%
1 week 0.94
Extreme 0.9376
1.04
1 month 0.88
Extreme 0.8823
1.04
Current year 0.88
Extreme 0.8823
1.98
1 year 0.88
Extreme 0.8823
2.09
3 years 0.37
Extreme 0.3651
2.09
5 years 0.37
Extreme 0.3651
2.71
10 years 0.37
Extreme 0.3651
3.96
Manager TitleAgeSince
Chief Executive Officer 54 17/09/2018
Director of Finance/CFO 50 14/11/2022
Chief Tech/Sci/R&D Officer - 01/04/2024
Director TitleAgeSince
Director/Board Member 60 01/07/2009
Director/Board Member 68 11/04/2014
Chairman 60 27/04/2024
Date Insider Type Main position Quantity % Market Cap. Importance
1/7/26 Free

Director

125,000 0.0501%
1/7/26
Broadwood Capital, Inc.
FreeCompany 125,000 0.0501%
1/7/26 Free

Director

125,000 0.0501%
Change 5-day change 1-year change 3-year change Capi.($)
+1.82%+4.36%-42.00%-10.18% 252M
-3.10%-3.43%+36.29%+67.69% 65.28B
+0.33%+0.33%+10.16%+78.07% 54.57B
+0.16%+1.73%+9.89%+102.10% 53.59B
-0.20%+1.97%+25.62%+51.79% 45.03B
-1.41%-4.87%+15.96%+114.60% 42.17B
+1.53%-5.28%+221.05%+900.40% 39.42B
-0.74%-4.84%+14.53%+44.45% 32.71B
-2.70%-7.34%+23.17%+0.36% 24.01B
+1.11%+15.18%+60.27%+49.33% 26.5B
Average -0.33%+2.24%+37.49%+139.86% 38.35B
Weighted average by Cap. -0.65%+1.72%+43.31%+155.33%

Financials

2026 *2027 *
Net sales 15.19M 13.64M 12.59M 11.42M 21.34M 1.44B 21.6M 151M 59.95M 756M 57.03M 55.81M 2.4B 16.83M 15.11M 13.95M 12.65M 23.64M 1.6B 23.94M 167M 66.43M 838M 63.19M 61.84M 2.66B
Net income -22.64M -20.32M -18.76M -17.01M -31.8M -2.15B -32.19M -225M -89.34M -1.13B -84.99M -83.17M -3.57B -34.44M -30.91M -28.54M -25.88M -48.37M -3.27B -48.97M -342M -136M -1.71B -129M -127M -5.44B
Net Debt - -
Projected Income Statement - Annual - Lineage Cell Therapeutics, Inc.
Logo Lineage Cell Therapeutics, Inc.
Lineage Cell Therapeutics, Inc. is a clinical-stage biotechnology company developing cell replacement therapies to treat serious medical conditions. The Company programs are based on a cell-based technology platform, AlloSCOPE, which develops formulation, manufacturing, and delivery capabilities, and serves as the source of its pluripotent cell-based product candidates. Its pipeline includes OpRegen, an allogeneic retinal pigment epithelial (RPE) cell replacement therapy for the treatment of geographic atrophy (GA) secondary to age-related macular degeneration (dry-AMD); OPC1, an allogeneic oligodendrocyte progenitor cell therapy for the treatment of spinal cord injuries (SCI); ReSonance (ANP1), an allogeneic auditory neuron progenitor cell transplant therapy for the treatment of auditory neuropathy; ILT1, an allogeneic cell transplant research initiative for the treatment of Type 1 Diabetes (T1D).
Employees
75
Date Price Change Volume
28/10/26 US$1.020 +2.32% 793,020
26/10/26 US$0.9969 -0.31% 1,908,142
23/10/26 US$1.000 +1.52% 1,150,709
22/10/26 US$0.9850 +3.52% 1,346,738
21/10/26 US$0.9515 -2.17% 1,220,810
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
MarketScreener Ratings - Lineage Cell Therapeutics, Inc.
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
7
Last Close Price
0.9969USD
Average target price
5.500USD
Spread / Average Target
+451.71%

Quarterly revenue - Rate of surprise

Rate of surprise - Net sales - Quarterly - Lineage Cell Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. LCTX Stock